In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns

Respiratory Care

Volumn 54, Issue 12, 2009, Pages 1671-1678

  Berg, Elna B ^a   Picard, Robert J ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b NONE

Author keywords

Budesonide inhalation suspension; In vitro; Nebulizer

Indexed keywords

BUDESONIDE;

AEROSOL; AIRFLOW; ARTICLE; BREATHING PATTERN; CHILD; CHILD CARE; DRUG DELIVERY SYSTEM; FILTER; GEOMETRY; HOME CARE; HUMAN; IN VITRO STUDY; INFANT; JET VENTILATION; MEASUREMENT; NEBULIZATION; NEBULIZER; SIMULATOR; STANDARDIZATION;

ADOLESCENT; AEROSOLS; BUDESONIDE; CHILD; CHILD, PRESCHOOL; GLUCOCORTICOIDS; HUMANS; INFANT; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE;

EID: 73449096131     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Rau JL. The inhalation of drugs: advantages and problems. Respir Care 2005;50(3):367-382.
2. Smaldone GC. Advances in aerosols: adult respiratory disease. J Aerosol Med 2006;19(1):36-46.
3. Berg E, Svensson JO. Establishing standardised methods for comparing aqueous droplet inhalers. Pharmeur Sci Notes 2006;(2):9-15.
4. Nikander K, Berg E, Smaldone GC. Jet nebulizers versus pressurized metered dose inhalers with valve holding chambers effects of the facemask on aerosol delivery. J Aerosol Med 2007;20(Suppl 1):S46-S58.
5. Smaldone GC, Berg E, Nikander K. Variation in pediatric aerosol delivery: importance of facemask. J Aerosol Med 2005;18(3):354-363.
6. Berger WE. Budesonide inhalation suspension for the treatment of asthma in infants and children. Drugs 2005;65(14):1973-1989.
7. Berger WE, Qaqundah PY, Blake K, Rodriguez-Santana J, Irani AM, Xu J, Goldman M. Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze. J Pediatr 2005;146(1):91-95.
8. Leflein JG, Baker JW, Eigen H, Lyzell E, McDermott L. Safety features of budesonide inhalation suspension in the long-term treatment of asthma in young children. Adv Ther 2005;22(3):198-207.
9. Smaldone GC, Cruz-Rivera M, Nikander K. In vitro determination of inhaled mass and particle distribution for budesonide nebulizing suspension. J Aerosol Med 1998;11:113-125.
10. Szefler SJ, Eigen H. Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol 2002;109(4):730-742.
11. Berg E, Svensson JO, Asking L. Determination of nebulizer droplet size distribution: a method based on impactor refrigeration. J Aerosol Med 2007;20(2):97-104.
12. Berg E, Lamb P, Ali A, Dennis J, Tservistas M, Mitchell J. Assessment of the need to coat particle collection cups of the NGI to mitigate droplet bounce when evaluating nebuliser-produced droplets. Pharmeur Sci Notes 2008;(1):21-25.
13. Dennis J, Berg E, Sandell D, Ali A, Lamb P, Tservistas M, et al. Cooling the NGI - an approach to size a nebulised aerosol more accurately. Pharmeur Sci Notes 2008;(1):27-30.
14. Marple VA, Olson BA, Santhanakrishnan K, Roberts DL, Mitchell JP, Hudson- Curtis BL. Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III: Extension of archival calibration to 15 L/min. J Aerosol Med 2004;17(4):335-343.
15. Zhou Y, Ahuja A, Irvin CM, Kracko DA, McDonald JD, Cheng YS. Medical nebulizer performance: effects of cascade impactor temperature. Respir Care 2005;50(8):1077-1082.
16. United States Pharmacoepia 31. General chapter 601. Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers. 2008.
17. Dolovich MB, Mitchell JP. Canadian Standards Association standard CAN/CSA/Z264.1-02:2002: A new voluntary standard for spacers and holding chambers used with pressurized metered-dose inhalers. Can Respir J 2004;11(7):489-495.
18. Jauernig J, Mitchell J, Berg E, Dennis J, Kreher C, Lamb P, et al. Recommendation on the adoption of breathing patterns for infants and small children in general. Chapter 2.9.44 Preparations for nebulisation. Pharmeur Sci Notes 2008;(1):31-32.
19. O'Callaghan C, White J, Jackson J, Barry P, Kantar A. The output of flunisolide from different nebulisers. J Pharm Pharmacol 2002;54(4):565-569.
20. O'Callaghan C, White J, Jackson J, Barry PW, Kantar A. Delivery of nebulised budesonide is affected by nebuliser type and breathing pattern. J Pharm Pharmacol 2005;57(6):787-790.
21. Nikander K, Bisgaard H. Impact of constant and breath-synchronized nebulization on inhaled mass of nebulized budesonide in infants and children. Pediatr Pulmonol 1999;28(3):187-193.
22. Nikander K, Agertoft L, Pedersen S. Breath-synchronized nebulization diminishes the impact of patient-device interfaces (face mask or mouthpiece) on the inhaled mass of nebulized budesonide. J Asthma 2000;37(5):451-459.
23. de Blic J, Delacourt C, Le Bourgeois M, Mahut B, Ostinelli J, Caswell C, Scheinmann P. Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study. J Allergy Clin Immunol 1996;98(1):14-20.
24. Ilangovan P, Pedersen S, Godfrey S, Nikander K, Noviski N, Warner JO. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child 1993;68(3):356-359.
25. Wennergren G, Nordvall SL, Hedlin G, Möller C, Wille S, Åsbrink Nilsson E. Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers. Acta Paediatr 1996;85(2):183-189.
26. Volovitz B, Soferman R, Blau H, Nussinovitch M, Varsano I. Rapid induction of clinical response with a short-term high-dose starting schedule of budesonide nebulizing suspension in young children with recurrent wheezing episodes. J Allergy Clin Immunol 1998;101(4 Pt 1):464-469.